However, as indicated above, CD47 is widely expressed on virtually all cells in the body, and, particularly, hematologic adverse events are often observed in patients treated with anti-CD47 mAbs, e.g., anemia, thrombocytopenia, lymphopenia, and neutropenia. The gene discussed is CD47; the disease is Thrombocytopenia.